The project will process over 60,000 serum samples using the Nulisaseq Immune 340 and Nulisaseq Neuro 220 panels. By cataloging these proteins, researchers intend to identify distinct biological subtypes within patient populations that currently share identical clinical diagnoses. This granular approach seeks to address historical challenges in drug development where non-uniform disease elements have hindered therapeutic progress.

Alamar’s proprietary platform enables the detection of protein biomarkers at extremely low concentrations, providing the ultra-high sensitivity required for such a massive dataset. The collaboration focuses on generating actionable insights that could eventually refine precision prevention strategies and shift the timeline for early disease detection in real-world clinical environments.